Harmony Biosciences Holdings, Inc.HRMYEarnings & Financial Report
Harmony Biosciences Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological and central nervous system disorders. Its primary market is the United States, with its core product serving patients living with narcolepsy and other sleep-related CNS conditions across adult and pediatric segments.
HRMY Q4 FY2025 Key Financial Metrics
Revenue
$243.8M
Gross Profit
$175.2M
Operating Profit
$38.6M
Net Profit
$22.5M
Gross Margin
71.9%
Operating Margin
15.8%
Net Margin
9.2%
YoY Growth
21.1%
EPS
$0.38
Harmony Biosciences Holdings, Inc. Q4 FY2025 Financial Summary
Harmony Biosciences Holdings, Inc. reported revenue of $243.8M (up 21.1% YoY) for Q4 FY2025, with a net profit of $22.5M (down 54.6% YoY) (9.2% margin). Cost of goods sold was $68.5M, operating expenses totaled $136.7M.
Key Financial Metrics
| Total Revenue | $243.8M |
|---|---|
| Net Profit | $22.5M |
| Gross Margin | 71.9% |
| Operating Margin | 15.8% |
| Report Period | Q4 FY2025 |
Harmony Biosciences Holdings, Inc. Annual Revenue by Year
Harmony Biosciences Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $868.5M).
Harmony Biosciences Holdings, Inc. Quarterly Revenue & Net Profit History
Harmony Biosciences Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $243.8M | +21.1% | $22.5M | 9.2% |
| Q3 FY2025 | $239.5M | +28.7% | $50.9M | 21.2% |
| Q2 FY2025 | $200.5M | +16.0% | $39.8M | 19.8% |
| Q1 FY2025 | $184.7M | +19.5% | $45.6M | 24.7% |
| Q4 FY2024 | $201.3M | +19.5% | $49.5M | 24.6% |
| Q3 FY2024 | $186.0M | +16.1% | $46.1M | 24.8% |
| Q2 FY2024 | $172.8M | +28.8% | $11.6M | 6.7% |
| Q1 FY2024 | $154.6M | +29.8% | $38.3M | 24.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $154.6M | $172.8M | $186.0M | $201.3M | $184.7M | $200.5M | $239.5M | $243.8M |
| YoY Growth | 29.8% | 28.8% | 16.1% | 19.5% | 19.5% | 16.0% | 28.7% | 21.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $847.0M | $858.4M | $928.1M | $999.2M | $1.06B | $1.11B | $1.21B | $1.27B |
| Liabilities | $331.6M | $319.8M | $331.3M | $340.0M | $335.0M | $334.9M | $373.1M | $401.4M |
| Equity | $515.4M | $538.6M | $596.8M | $659.2M | $720.5M | $773.1M | $835.1M | $870.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $31.1M | $42.6M | $70.5M | $75.6M | $34.0M | $79.3M | $108.7M | $126.2M |